<DOC>
	<DOCNO>NCT00734864</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) dasatinib combine protracted , daily temozolomide ( TMZ ) . Secondary objective : To evaluate safety tolerability dasatinib plus protracted , daily TMZ ; 2 . To evaluate pharmacokinetics dasatinib administer protracted , daily TMZ among recurrent malignant glioma patient CYP-3A enzyme induce anti-epileptic drug ( EIAEDs ) ; 3 . To evaluate anti-tumor activity regimen patient population .</brief_summary>
	<brief_title>Ph . I Dasatinib/Protracted Temozolomide Recurrent Malignant Glioma</brief_title>
	<detailed_description>This open-label , single center , one-arm phase I dose-escalation study dasatinib plus protracted , daily TMZ administer orally continuous daily dose schedule among adult patient recurrent relapse malignant glioma . The study format include classical `` 3+3 '' dose escalation design determine MTD DLT dasatinib plus protracted , daily TMZ among recurrent malignant glioma patient . Patients stratify base whether receive EIAED stratum independently dose escalate . Additionally , study characterize safety , tolerability , biologic activity , pharmacokinetic profile dasatinib use combination protract , daily TMZ . Patients start treatment day 1 cycle 1 dasatinib . For patient undergo dasatinib pharmacokinetic ( PK ) analysis , dasatinib administer alone initial PK assessment collect . Protracted TMZ initiated initial dasatinib PK assessment collect continue administer dasatinib continuous daily dose schedule . The initial dasatinib PK assessment collect 24 hour day 3-7 cycle 1 . Patients undergo dasatinib PK collection begin dasatinib protract , daily TMZ together day 1 , cycle 1 . The protracted , daily TMZ dose 50 mg/mÂ² daily patient . The dose level dasatinib increase successive cohort . Cohorts 3-6 patient accrue dose level MTD define . Each cohort consist minimum 3 newly enrol patient . Intra-patient dose escalation permit . It estimate study enroll minimum 30 patient ( 4 dose levels/stratum ; 3 patients/dose level level 1-3 6 patient level 4 ) maximum 48 patient ( 6 patients/dose level ; 4 dose levels/stratum ) . Cohorts may expand dose level elaboration safety pharmacokinetic parameter require . The primary safety efficacy analysis conduct patient data time patient still receive study drug complete least 4 cycle treatment . The additional data patient continue receive study drug past time , allow protocol , summarized report patient either complete discontinued study . Prior primary analysis , additional safety report may prepare . The common side effect include vomit , diarrhea , anorexia ( loss appetite ) , fluid retention , fatigue , headache , rash , hypocalcemia ( low calcium level ) , decrease blood count . Other possible side effect may include nausea , joint pain , muscle ache , generalize pain , abdominal pain , fever . Rare side effect may include QTc prolongation ( heart beat change ) , pulmonary edema ( fluid around lung ) , difficulty breathing , cough , hemorrhage , gastrointestinal bleeding , pneumonia , cardiac effusion ( fluid sac surround heart ) , cardiac failure . Temodar well tolerate adult child common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , hepatotoxicity , anorexia , fatigue hyperglycemia . As case many anti-cancer drug , Temodar may carcinogenic . Rats give Temodar develop breast cancer .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>1 . Patients must histologically confirm diagnosis recurrent/progressive WHO Gr.4 malignant glioma ( glioblastoma multiforme gliosarcoma ) WHO Gr.3 malignant glioma ( anaplastic astrocytoma , anaplastic oligodendroglioma anaplastic mixed glioma ) . Recurrence define base modify MacDonald criterion base histopathologic confirmation tissue obtain via surgical intervention . Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation WHO Gr.III IV malignant glioma ; 2 . &gt; = 18 y/o ; 3 . KPS . = 60 % ; 4 . Patients must present 1st , 2nd 3rd relapse . Relapse define progression follow anticancer therapy surgery , include nonsurgical therapy consider standard treatment highgrade glioma administer patient prior lowgrade glioma . Prior therapy must include external beam radiotherapy ; 5 . Adequate bone marrow , liver renal function assess follow : Hematocrit &gt; = 29 % , ANC &gt; = 1,500/mm3 , Platelet count &gt; = 125,000/mm3 , Total bilirubin &lt; = 1.5 x ULN , ALT AST &lt; = 2.5 x ULN ( &lt; = 5 x ULN patient liver involvement ) , INR &lt; 1.5 PT/PTT within normal limit ( unless therapeutic anticoagulation ) . Patients receive anticoagulation treatment lowmolecular weight heparin allow participate , however oral warfarin permit except lowdose warfarin ( 1mg po DAILY ) , Creatinine &lt; 1.5 x ULN , Serum Na , K+ , Mg2+ , Phosphate Ca2+ &gt; = Lower Limit Normal ( LLN ) ; 6 . An interval least 2 week prior surgical resection ( 1 week biopsy ) initiation study regimen ; 7 . An interval least 12 week completion standard , daily XRT , unless one follow occurs : ) new area enhancement MRI image outside XRT field ; b ) biopsy proven recurrent tumor ; c ) radiographic evidence progressive tumor 2 consecutive scan least 4 week apart ; 8 . An interval least 4 week prior chemotherapy ( except nitrosoureas require 6 week ) unless unequivocal evidence tumor progression patient recover anticipated toxicity prior therapy ; 9 . An interval least 14 day exposure investigational agent , unless unequivocal evidence tumor progression patient recover anticipated toxicity prior therapy ; 10 . Signed write informed consent include HIPAA accord institutional guideline . A sign informed consent must obtain prior study specific procedure ; 11 . If sexually active , patient take contraceptive measure duration treatment 3 month follow discontinuation dasatinib TMZ ; 12 . Women childbearing potential must negative serum urine pregnancy test ( sensitivity &lt; = 25IU HCG/L ) within 72 hour prior start study drug administration . 1 . Prior dasatinib . Imatinib mesylate prior three month ; 2 . Grade 3 great toxicity relate prior TMZ therapy ; 3 . Prior progression protract daily TMZ ; 4 . Pregnancy breast feeding ; 5 . History significant concurrent illness ; 6 . More 3 prior episode progressive disease ; 7 . Significant cardiac disease include follow : 1. congestive heart failure &gt; class II NYHA ; 2. unstable angina ( anginal symptom rest ) ; 3. new onset angina ( begin within last 3 month ) ; 4. myocardial infarction within past 6 month ; 5. history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; 6. uncontrolled congestive heart failure ; diagnose congenital long QT syndrome ; prolong QTc interval preentry electrocardiogram ( &gt; 450 msec ) ; 8 . Excessive risk bleeding define stroke within prior 6 month , history CNS intraocular bleed , septic endocarditis ; 9 . Female patient pregnant breastfeeding , adult reproductive potential employ effective method birth control . ( Women childbearing potential must negative serum pregnancy test within 72 hour prior administration study regimen ) . Sexually active woman childbearing potential ( WOCBP ) must use effective method birth control course study , manner risk failure minimize . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy ; 10 . Concurrent severe and/or uncontrolled medical disease could compromise participation study pleural pericardial effusion grade , uncontrolled diabetes , uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management ) , active clinically serious infection &gt; CTCAE Gr.2 , history clinically significant bleed diathesis coagulopathy include platelet function disorder ( e.g . know von Willebrand 's disease ) acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) , impairment GI function GI disease may significantly alter absorption study regimen ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) , ongoing recent ( &lt; = 3 month ) significant gastrointestinal bleeding ; 11 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month ; 12 . Any hemorrhage/bleeding event &gt; CTCAE Gr.3 within 4 week 1st dose study drug ; 13 . Serious nonhealing wound , ulcer , bone fracture ; 14 . Major surgery , open biopsy significant traumatic injury within 4 week 1st study drug ; 15 . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C ; 16 . Patient &lt; 3 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow ; 17 . Patient unwilling unable comply protocol include ability swallow whole pill presence malabsorption syndrome ; 18 . Concurrent administration warfarin , rifampin St. John 's Wort , except lowdose warfarin ( 1mg po DAILY ) ; 19 . Clinically serious infection require active intervention ( CTCAE Gr.2 great ) ; 20 . Hypokalemia hypomagnesemia correct ; 21 . Concomitant Medications , consider follow prohibition : 1 . Drugs generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) 1. quinidine , procainamide , disopyramide 2. amiodarone , sotalol , ibutilide , dofetilide 3. erythromycin , clarithromycin 4. chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide 5. cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 2 . Drugs reduce dasatinib exposure H2 blocker protonpump inhibitor ( eg famotidine omeprazole ) , cause longterm suppression gastric acid secretion . The concomitant use H2 blocker proton pump inhibitor dasatinib general recommend antacid consider place H2 blocker proton pump inhibitor patient receive dasatinib therapy . However , give nearly recurrent malignant brain tumor patient dexamethasone increase intracranial pressure , patient must also receive effective medical therapy prevent complication relate increase gastric acid secretion due chronic dexamethasone therapy . Therefore patient enrolled current protocol receive standard H2 blocker ( prefer ) proton pump inhibitor ( PPI ) therapy administer daily basis evening . Dasatinib administer morning order maximize time interval administer H2 blocker ( prefer ) proton pump inhibitor ( PPI ) . 3 . Drugs cause hypocalcemia ( i.e . IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia ) . 4 . Any prohibited CYP3A4 inhibitor ; 22 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Dasatinib</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Recurrent Malignant Glioma</keyword>
	<keyword>Malignant Glioma</keyword>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>anaplastic astrocytoma</keyword>
	<keyword>anaplastic oligodendroglioma</keyword>
	<keyword>anaplastic mixed glioma</keyword>
	<keyword>glioma</keyword>
</DOC>